clinical trial · NCT07589569
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
Shandong Suncadia Medicine Co., Ltd.·phase2·not yet recruiting·n = 92
Pancreatic CancerHRS-7058
brief summary
This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.
started
May 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
May 15, 2026
official title
An Open, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol